The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.
 
Emily Hinchcliff
No Relationships to Disclose
 
Weiyi Peng
Research Funding - GlaxoSmithKline
 
Virginia Bayer
No Relationships to Disclose
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Steven Y Huang
Research Funding - Adient Medical
 
Rahul Sheth
No Relationships to Disclose
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; BioAscent; Casdin Capital; Clovis Oncology; Genentech; Gerson Lehrman Group; Medivation; Medscape; Merck; Ovation Sciences; Pfizer; Roche; Tesaro; Vaniam Group; Vermillion; Watermark Research Partners
Research Funding - ArQule; AstraZeneca; Bayer; Biomarin; Celgene (I); Clovis Oncology; Cotinga Pharmaceuticals; Critical Outcome Technologies; Karyopharm Therapeutics (I); Kite, a Gilead company (I); Novartis; Roche/Genentech; Tesaro
 
Karen H. Lu
No Relationships to Disclose
 
Patrick Hwu
Stock and Other Ownership Interests - Immatics
Consulting or Advisory Role - Dragonfly Therapeutics; GlaxoSmithKline; Immatics; Sanofi
Research Funding - Genentech (Inst)
 
Amir A. Jazaeri
Honoraria - Gerson Lehrman Group
Consulting or Advisory Role - Almac Group; Aravive; Genentech/Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune